Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status Prescription; Discontinued
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 22365-121; 51927-0168; 66039-829; 0395-8244; 0093-3133; 63629-8818; 64552-4008; 62147-0087; 51672-4145; 99207-270; 62350-0077; 99207-276; 68462-536; 62147-0072; 45802-368; 68682-272; 99207-260; 72189-084; 71052-160; 99207-271; 0168-0432; 51552-1538; 58175-0397; 11517-270; 72643-006; 11517-275; 51927-4898; 51672-4174; 11517-262
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Disease progression08.01.03.0380.002418%
Disease recurrence08.01.03.0500.002317%Not Available
Genital pain21.10.01.008--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Pigmentation disorder23.05.03.0010.003476%Not Available
Vaginitis bacterial21.14.02.010; 11.02.01.020--Not Available
Application site exfoliation23.03.07.007; 12.07.01.022; 08.02.01.022--Not Available
Oral mucosa erosion07.05.06.0090.003476%Not Available
Procedural pain12.02.05.007; 08.01.08.009--Not Available
Skin abrasion23.03.11.018; 12.01.06.010--Not Available
Application site burn23.03.11.013; 12.07.01.038; 08.02.01.038--Not Available
Application site cellulitis12.07.01.043; 11.02.01.028; 08.02.01.043; 23.09.01.016--Not Available
Application site erosion23.07.03.011; 12.07.01.021; 08.02.01.021--Not Available
Application site scab12.07.01.042; 23.03.03.050; 08.02.01.042--Not Available
Treatment failure08.06.01.0170.002418%Not Available
Oral herpes11.05.02.005; 07.05.07.0020.002317%Not Available
Anorectal discomfort07.03.03.003--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.004634%
Vulvovaginal pain21.08.02.009--
Neuropsychiatric syndrome19.07.03.009; 17.02.10.0140.002317%Not Available
Application site haemorrhage24.07.01.048; 12.07.01.040; 08.02.01.040--Not Available
Eye ulcer06.08.03.0180.002317%Not Available
Candida infection11.03.03.0210.002317%
Immune thrombocytopenic purpura10.04.01.008; 01.08.01.007--Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000604%
Malignant melanoma in situ23.08.01.004; 16.03.01.0040.002317%Not Available
Lip erosion07.05.01.0160.002317%Not Available
The 11th Page    First    Pre   11 12    Next   Last    Total 12 Pages